Immunology, Oncology, Diabetes. Company provides a highly specific antibody-based T-cell antagonist with broad application potential in T-cell mediated conditions, including transplant rejection, type 1 diabetes and pediatric acute lymphoblastic leukemia. Over 100 million people worldwide suffer from T-cell autoimmune disorders. The company was granted orphan drug status by the U.S. FDA in April 2009. Its antibody technology is ready for later stage trials and near-term market approval, based on the results of successful clinical trials. Founded: 2007.